Self-assesment Session
E³ 1221 - Breast lesions of uncertain malignant potential (B3 lesions): the management conundrum
Lectures
1
E³ 1221 - A. Imaging appearance of B3 lesions
24:26P. Baltzer, Vienna / Austria
Learning Objectives
1. To understand the entire spectrum of the lesions with uncertain malignant potential (B3).
2. To learn how B3 lesions appear on mammography, tomosynthesis, contrast-enhanced mammography, ultrasound, non-contrast and contrast-enhanced MRI.
3. To discuss their different biological behaviour in relation to contrast-enhanced imaging modalities.
2
E³ 1221 - B. The clinical management of B3 lesions
27:59S. Schiaffino, Milan / Italy
Learning Objectives
1. To distinguish between low and high-risk B3 lesions.
2. To know the impact of needle size and imaging guidance on exclusion of associated malignancy.
3. To learn how to discuss the clinical management of B3 lesions in the multidisciplinary meeting.
E³ 1221-1
A. Imaging appearance of B3 lesions
Pascal A.T. Baltzer, Vienna / Austria
Learning Objectives
1. To understand the entire spectrum of the lesions with uncertain malignant potential (B3).
2. To learn how B3 lesions appear on mammography, tomosynthesis, contrast-enhanced mammography, ultrasound, non-contrast and contrast-enhanced MRI.
3. To discuss their different biological behaviour in relation to contrast-enhanced imaging modalities.
2. To learn how B3 lesions appear on mammography, tomosynthesis, contrast-enhanced mammography, ultrasound, non-contrast and contrast-enhanced MRI.
3. To discuss their different biological behaviour in relation to contrast-enhanced imaging modalities.
E³ 1221-2
B. The clinical management of B3 lesions
Simone Schiaffino, Lugano / Switzerland
Learning Objectives
1. To distinguish between low and high-risk B3 lesions.
2. To know the impact of needle size and imaging guidance on exclusion of associated malignancy.
3. To learn how to discuss the clinical management of B3 lesions in the multidisciplinary meeting.
2. To know the impact of needle size and imaging guidance on exclusion of associated malignancy.
3. To learn how to discuss the clinical management of B3 lesions in the multidisciplinary meeting.